Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Piga, Antonio and Galanello, Renzo and Forni, Gian Luca and Cappellini, Maria Domenica and Origa, Raffaella and Zappu, Antonietta and Donato, Guido and Bordone, Laura and Lavagetto, Antonella and Zanaboni, Laura and Sechaud, Romain and Hewson, Nicola and Ford, John Malcolm and Opitz, Herbert and Alberti, Daniele Maria (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91 (7). pp. 873-880. ISSN 1592-8721

Abstract

Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious complications in the absence of chelation treatment to remove excess iron. Deferoxamine (Desferal, DFO) reduces morbidity and mortality although the administration schedule of slow, parenteral infusions several days each week limits compliance and negatively affects long-term outcome. Deferasirox (Exjade, ICL670) is an oral chelator with high iron-binding potency and selectivity. In a phase II study, the tolerability and efficacy of deferasirox were compared with those of DFO in 71 adults with transfusional hemosiderosis.

Item Type: Article
Related URLs:
Related URLs:
Date Deposited: 28 Jan 2012 00:45
Last Modified: 01 Feb 2013 00:46
URI: https://oak.novartis.com/id/eprint/5601

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.